Simbec-Orion Expands Immunoassay Capability
In line with our continuing investment in technology, we have recently expanded our immunoassay capability with the addition of a ...Read more >
News
Simbec-Orion to conduct a Phase II clinical trial in pulmonary sarcoidosis patients for Molecure's OATD-01
Warsaw, 3rd July 2023 Molecure has signed an agreement to conduct a Phase II clinical trial for its lead molecule ...Read more >
Welcome to Simon Jennings
We are delighted to share that Simon Jennings as joined Simbec-Orion as Vice President, Data Sciences. Simon has over 35 ...Read more >
Le groupe Simbec-Orion a reçu l’accréditation pour la taxe Recherche & Développement
Le groupe Simbec-Orion a reçu l’accréditation pour la taxe Recherche & Développement ‹‹CIR – Crédit d’Impôt Recherche›› qui donne droit ...Read more >
Steering Your Path to the Clinic, Complimentary Breakfast Workshop, June 29, Oxford UK
How confident are you in your route to the clinic? There are multiple hurdles to be navigated, many of which ...Read more >
Outsourcing Clinical Trials: Key Considerations for Sponsors
Outsourcing is common practice in clinical trials; as the global clinical research market becomes ever more competitive, small to mid-size ...Read more >
Common challenges in bioanalytical method development
The development of bioanalytical methods and subsequent quantification of analytes in a range of biological matrices is fundamental to the ...Read more >
Clinical Considerations for First-in-Human (FIH) and Early Phase Clinical Trials
You are coming close to having completed your nonclinical studies and you are beginning to think about your next steps. ...Read more >
Project Management for Clinical Trials
The world of medical research and development is constantly advancing, and clinical trials play a crucial role in bringing new ...Read more >
Nonclinical development strategies to optimise your clinical development programme
Being first to market with an innovator drug remains the ultimate goal for all, and most organisations are constantly reviewing ...Read more >
First Dose Administered in Phase I Trial of Novel Treatment for Cognitive Impairment Associated with Schizophrenia
February 27, 2023 Simbec-Orion are pleased to share that dosing with MDI-26478, Cardiff University’s Medicines Discovery Institute’s (MDI) potential novel ...Read more >
Mission Therapeutics Successfully Completes First Clinical Assessment for Lead DUB Program, MTX652
The successful delivery of another Phase I clinical trial by the team at Simbec-Orion has resulted in the achievement of ...Read more >